Skip to content

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04328298
Enrollment
5000
Registered
2020-03-31
Start date
2019-12-19
Completion date
2038-12-19
Last updated
2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopathology Eligible or CAR-t Cell Treatment

Brief summary

This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.

Interventions

None listed

Sponsors

The Lymphoma Academic Research Organisation
Lead SponsorOTHER
Gilead Sciences
CollaboratorINDUSTRY
Novartis
CollaboratorINDUSTRY
Bristol-Myers Squibb
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
0 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

Retrospective inclusion : * Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center * If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive Prospective inclusion : * Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center. * Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019 * Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019 * If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.

Exclusion criteria

Patient not registered with the social security in France

Design outcomes

Primary

MeasureTime frame
overall survival from eligibility15 years
Overall survival from administration15 years
complete response rate15 years
Progression free survival15 years
Duration of response15 years
Delays between patient eligibility and CAR-T treatment15 years

Countries

France

Contacts

CONTACTKarine Danno
descar-t@lysarc.org+33 (04) 72 66 93 33
PRINCIPAL_INVESTIGATORSteven LE GOUILL, Pr

Institut Curie

PRINCIPAL_INVESTIGATORRoch HOUOT, Pr

CHU Pontchaillou

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 23, 2026